Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Roivant Sciences ( (ROIV) ) is now available.
On December 11, 2025, Roivant Sciences hosted its Investor Day, highlighting significant progress in its pipeline and outlining its growth strategy. The company announced plans for multiple product launches and filings over the next three years, including brepocitinib for dermatomyositis, with a commercial launch expected in early 2027. Roivant also reported positive updates on clinical trials, including accelerated timelines for brepocitinib in non-infectious uveitis and cutaneous sarcoidosis, as well as the IMVT-1402 trial for rheumatoid arthritis. Additionally, Roivant’s financing efforts have extended Immunovant’s cash runway to support the launch of IMVT-1402 in Graves’ disease, positioning the company for long-term shareholder value creation.
The most recent analyst rating on (ROIV) stock is a Hold with a $22.50 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.
Spark’s Take on ROIV Stock
According to Spark, TipRanks’ AI Analyst, ROIV is a Neutral.
Roivant Sciences’ overall stock score is driven by strong technical indicators and positive sentiment from recent corporate events and earnings call. However, financial performance and valuation concerns, including negative profitability and cash flow challenges, weigh down the score. The company’s strategic advancements in its pipeline and strong financial position provide a positive outlook, but operational improvements are necessary to enhance profitability.
To see Spark’s full report on ROIV stock, click here.
More about Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on accelerating the development and commercialization of medicines. The company’s pipeline includes brepocitinib, a JAK1 and TYK2 inhibitor for dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis; IMVT-1402 and batoclimab, monoclonal antibodies targeting FcRn for autoimmune diseases; and mosliciguat, an inhaled sGC activator for pulmonary hypertension associated with interstitial lung disease. Roivant operates through subsidiaries known as ‘Vants’ and also incubates health technology startups.
Average Trading Volume: 7,996,642
Technical Sentiment Signal: Buy
Current Market Cap: $14.21B
Learn more about ROIV stock on TipRanks’ Stock Analysis page.